drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (genetically engineered CAR-NK cells)
drug_description
Cord blood–derived natural killer (NK) cells genetically engineered to express a CD19-directed chimeric antigen receptor for antigen-specific recognition and cytotoxic killing of CD19-positive B cells in B-cell malignancies.
nci_thesaurus_concept_id
C170903
nci_thesaurus_definition
A preparation of natural killer (NK) cells engineered to express an inhibitory chimeric antigen receptor (iCAR) specific for the tumor-associated antigen (TAA) cluster of differentiation 19 (CD19), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19 iCAR-NK cells recognize, bind to and induce selective cytotoxicity in CD19-expressing tumor cells. The iCAR is designed to spare normal cells from NK cell actions by including an inhibitory receptor that is activated upon binding to antigens that are present on normal cells only. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Cord blood–derived NK cells are engineered to express a CD19-specific chimeric antigen receptor, enabling antigen-dependent recognition and cytotoxic killing of CD19-positive B cells in B-cell malignancies. In this construct, IL-15 supports NK activation, proliferation, and persistence, while IL-10 modulates inflammatory responses to enhance antitumor activity and potentially reduce toxicity.
drug_name
anti-CD19 CAR-NK cells
nct_id_drug_ref
NCT06707259